The Swedish Life Science Investor Meeting is being held for the second consecutive year, with SmiLe Incubator as a co-arranger. Over 40 of Sweden’s best life science startup companies and some 40 international investors meet there at scheduled individual partnering meetings. SmiLe companies Acorai, Amplio and Xinnate are participating in the digital event, which is being held on November 17 and 18.
Swedish life science startup companies that meet high standards for testing their ideas or technologies have been invited to apply to attend the Swedish Life Science Investor Meeting. This year’s investors include Abbvie Ventures, Pfizer Ventures, European Investment Bank, Industrifonden, Kurma Partners and Sunstone.
SmiLe Incubator arranges the event together with GU Ventures, Karolinska Institutet Innovations, Lead, Medeon Science Park & Incubator, Sahlgrenska Science Park, Sting, Umeå Biotech Incubator and Uppsala Innovation Centre. The incubators belong to the Association of Life Science Incubators of Sweden (ALIS), a group of life science incubators that collaborate and pursue common interests.
“We’ve created an arena where we offer international investors the opportunity to meet the most interesting companies in Swedish life science incubators. This year’s event has a fantastic turnout of international investors, more than we’ve seen in a long time. Last year’s event was greatly appreciated by the investors. This year’s registrations show that we have established a new Swedish investor event for early-stage life science companies, which is important for our entrepreneurs, as well as for Swedish industry,” says Thomas Unt, SmiLe Business Coach VC Relations & Finance, CEO of SmiLe Inject Capital.
For more information, please contact: Thomas Unt, SmiLe Business Coach VC Relations & Finance, vd SmiLe Inject Capital, +46 (0)708 201070, email@example.com
Read more about the event: https://swedish-life-science-meets-investors.b2match.io/
Information about the companies:
Acorai – is redefining heart failure monitoring by enabling non-invasive intracardiac pressure monitoring to help reduce heart failure re-hospitalizations.
Amplio Pharma – is a pharmaceutical company which develops proprietary drug products that amplify the efficacy of pharmaceutical treatments in a significant manner. With its lead candidate AMP101, the company intends to double the number of patients benefitting from the 1st line rheumatoid arthritis treatment.
Xinnate – develops proprietary peptides for prevention and treatment of wound and topical applications. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations.
Photo: Filip Peters – CEO Acorai, Karin von Wachenfeldt – CEO Amplio Pharma, and Helene Hartman – CEO Xinnate